Birinapant sensitizes platinum-resistant carcinomas with high levels of cIAP to carboplatin therapy
Combination therapy: sensitizing platinum-resistant tumors Carboplatin efficacy can be restored by administering it with birinapant, a drug combination that targets platinum-resistant cancer cells. Platinum-based chemotherapeutics are used to treat almost 50% of cancer patients. Despite excellent in...
| Main Authors: | , , , , , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Nature Portfolio
2017-04-01
|
| Series: | npj Precision Oncology |
| Online Access: | https://doi.org/10.1038/s41698-017-0008-z |
| _version_ | 1797430815077957632 |
|---|---|
| author | V. La R. Fujikawa D. M. Janzen M. Nunez L. Bainvoll L. Hwang K. Faull G. Lawson S. Memarzadeh |
| author_facet | V. La R. Fujikawa D. M. Janzen M. Nunez L. Bainvoll L. Hwang K. Faull G. Lawson S. Memarzadeh |
| author_sort | V. La |
| collection | DOAJ |
| description | Combination therapy: sensitizing platinum-resistant tumors Carboplatin efficacy can be restored by administering it with birinapant, a drug combination that targets platinum-resistant cancer cells. Platinum-based chemotherapeutics are used to treat almost 50% of cancer patients. Despite excellent initial response rates, tumor growth recurs in most patients as they develop resistance to therapy. Sanaz Memarzadeh and colleagues at the University of California, Los Angeles, show that the addition of birinapant to carboplatin eliminates platinum-resistant ovarian cancer cells by degrading the cell death-inhibiting proteins cIAP1 and cIAP2. Carboplatin and birinapant co-therapy restored the efficacy of the chemotherapeutic in human tumor samples and in mice with platinum-resistant tumors. Furthermore, the levels of cIAP protein in the resistant cells were predictive of the therapeutic response. These findings will help to select clinical trial patients that are most likely to benefit from this combination therapy. |
| first_indexed | 2024-03-09T09:33:00Z |
| format | Article |
| id | doaj.art-7a7a5d26d3d140b79e1df58bdb310f23 |
| institution | Directory Open Access Journal |
| issn | 2397-768X |
| language | English |
| last_indexed | 2024-03-09T09:33:00Z |
| publishDate | 2017-04-01 |
| publisher | Nature Portfolio |
| record_format | Article |
| series | npj Precision Oncology |
| spelling | doaj.art-7a7a5d26d3d140b79e1df58bdb310f232023-12-02T03:06:45ZengNature Portfolionpj Precision Oncology2397-768X2017-04-011111010.1038/s41698-017-0008-zBirinapant sensitizes platinum-resistant carcinomas with high levels of cIAP to carboplatin therapyV. La0R. Fujikawa1D. M. Janzen2M. Nunez3L. Bainvoll4L. Hwang5K. Faull6G. Lawson7S. Memarzadeh8Department of Obstetrics and Gynecology, David Geffen School of Medicine, University of California Los AngelesDepartment of Obstetrics and Gynecology, David Geffen School of Medicine, University of California Los AngelesDepartment of Obstetrics and Gynecology, David Geffen School of Medicine, University of California Los AngelesDepartment of Obstetrics and Gynecology, David Geffen School of Medicine, University of California Los AngelesDepartment of Obstetrics and Gynecology, David Geffen School of Medicine, University of California Los AngelesDepartment of Psychiatry and Biobehavioral Sciences, David Geffen School of Medicine, University of California Los AngelesDepartment of Psychiatry and Biobehavioral Sciences, David Geffen School of Medicine, University of California Los AngelesOffice of Laboratory Animal Care, University of California BerkeleyDepartment of Obstetrics and Gynecology, David Geffen School of Medicine, University of California Los AngelesCombination therapy: sensitizing platinum-resistant tumors Carboplatin efficacy can be restored by administering it with birinapant, a drug combination that targets platinum-resistant cancer cells. Platinum-based chemotherapeutics are used to treat almost 50% of cancer patients. Despite excellent initial response rates, tumor growth recurs in most patients as they develop resistance to therapy. Sanaz Memarzadeh and colleagues at the University of California, Los Angeles, show that the addition of birinapant to carboplatin eliminates platinum-resistant ovarian cancer cells by degrading the cell death-inhibiting proteins cIAP1 and cIAP2. Carboplatin and birinapant co-therapy restored the efficacy of the chemotherapeutic in human tumor samples and in mice with platinum-resistant tumors. Furthermore, the levels of cIAP protein in the resistant cells were predictive of the therapeutic response. These findings will help to select clinical trial patients that are most likely to benefit from this combination therapy.https://doi.org/10.1038/s41698-017-0008-z |
| spellingShingle | V. La R. Fujikawa D. M. Janzen M. Nunez L. Bainvoll L. Hwang K. Faull G. Lawson S. Memarzadeh Birinapant sensitizes platinum-resistant carcinomas with high levels of cIAP to carboplatin therapy npj Precision Oncology |
| title | Birinapant sensitizes platinum-resistant carcinomas with high levels of cIAP to carboplatin therapy |
| title_full | Birinapant sensitizes platinum-resistant carcinomas with high levels of cIAP to carboplatin therapy |
| title_fullStr | Birinapant sensitizes platinum-resistant carcinomas with high levels of cIAP to carboplatin therapy |
| title_full_unstemmed | Birinapant sensitizes platinum-resistant carcinomas with high levels of cIAP to carboplatin therapy |
| title_short | Birinapant sensitizes platinum-resistant carcinomas with high levels of cIAP to carboplatin therapy |
| title_sort | birinapant sensitizes platinum resistant carcinomas with high levels of ciap to carboplatin therapy |
| url | https://doi.org/10.1038/s41698-017-0008-z |
| work_keys_str_mv | AT vla birinapantsensitizesplatinumresistantcarcinomaswithhighlevelsofciaptocarboplatintherapy AT rfujikawa birinapantsensitizesplatinumresistantcarcinomaswithhighlevelsofciaptocarboplatintherapy AT dmjanzen birinapantsensitizesplatinumresistantcarcinomaswithhighlevelsofciaptocarboplatintherapy AT mnunez birinapantsensitizesplatinumresistantcarcinomaswithhighlevelsofciaptocarboplatintherapy AT lbainvoll birinapantsensitizesplatinumresistantcarcinomaswithhighlevelsofciaptocarboplatintherapy AT lhwang birinapantsensitizesplatinumresistantcarcinomaswithhighlevelsofciaptocarboplatintherapy AT kfaull birinapantsensitizesplatinumresistantcarcinomaswithhighlevelsofciaptocarboplatintherapy AT glawson birinapantsensitizesplatinumresistantcarcinomaswithhighlevelsofciaptocarboplatintherapy AT smemarzadeh birinapantsensitizesplatinumresistantcarcinomaswithhighlevelsofciaptocarboplatintherapy |